Bristol-Myers Squibb Co
NYSE:BMY

Watchlist Manager
Bristol-Myers Squibb Co Logo
Bristol-Myers Squibb Co
NYSE:BMY
Watchlist
Price: 51.95 USD 1.94% Market Closed
Market Cap: 105.8B USD

Bristol-Myers Squibb Co
Net Change in Cash

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Bristol-Myers Squibb Co
Net Change in Cash Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Change in Cash CAGR 3Y CAGR 5Y CAGR 10Y
Bristol-Myers Squibb Co
NYSE:BMY
Net Change in Cash
$7.8B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Net Change in Cash
-$1.7B
CAGR 3-Years
35%
CAGR 5-Years
N/A
CAGR 10-Years
-26%
Pfizer Inc
NYSE:PFE
Net Change in Cash
$242m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-10%
Merck & Co Inc
NYSE:MRK
Net Change in Cash
$3.6B
CAGR 3-Years
43%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zoetis Inc
NYSE:ZTS
Net Change in Cash
$370m
CAGR 3-Years
N/A
CAGR 5-Years
-27%
CAGR 10-Years
N/A
Eli Lilly and Co
NYSE:LLY
Net Change in Cash
$6.4B
CAGR 3-Years
N/A
CAGR 5-Years
26%
CAGR 10-Years
56%
No Stocks Found

Bristol-Myers Squibb Co
Glance View

Bristol-Myers Squibb Co., with its storied history stretching back over 100 years, has cemented its place among the giants in the pharmaceutical industry. Rooted in a relentless quest for innovation, the company is a powerhouse in biopharmaceuticals, specializing in the development of groundbreaking medicines to address some of the world's most pressing medical challenges. From its vast portfolio, Bristol-Myers Squibb focuses on creating treatments that profoundly improve and extend lives, targeting conditions like cancer, cardiovascular diseases, and immune disorders. This sharp focus on specific therapeutic areas allows the company to leverage its research acumen and clinical expertise fully. It consistently nurtures innovation through robust investment in research and development, collaborating with universities, research institutes, and biotechnology firms to stay ahead in a fiercely competitive field. Making money in the pharmaceutical sector involves a delicate dance of science, strategic marketing, and regulatory navigation, and Bristol-Myers Squibb has mastered this choreography. The company generates revenue primarily through the sale of its prescription medications, which follow a comprehensive journey from initial R&D and clinical trials through rigorous regulatory approval processes and, ultimately, to market launch. Blockbuster drugs like Opdivo and Eliquis, which cater to oncology and cardiovascular therapy markets respectively, bring in substantial revenue, driven by their efficacy and the global demand for effective treatments. Moreover, the company's commitment to expanding its pipeline ensures a steady flow of new products and maintains its competitive edge. By continually evaluating its portfolio and capitalizing on emerging medical needs, Bristol-Myers Squibb not only sustains its financial health but also solidifies its reputation as a leader in transforming patients' futures.

BMY Intrinsic Value
72.37 USD
Undervaluation 28%
Intrinsic Value
Price

See Also

What is Bristol-Myers Squibb Co's Net Change in Cash?
Net Change in Cash
7.8B USD

Based on the financial report for Sep 30, 2025, Bristol-Myers Squibb Co's Net Change in Cash amounts to 7.8B USD.

What is Bristol-Myers Squibb Co's Net Change in Cash growth rate?
Net Change in Cash CAGR 1Y
2 310%

Over the last year, the Net Change in Cash growth was 2 310%.

Back to Top